Company news
XBiotech Inc. news in 2023
XBiotech Inc.'s news releases, calls and decks from 2023, newest first.
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
September 25, 2023
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
August 29, 2023
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
August 7, 2023
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 21, 2023
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 16, 2023
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 16, 2023